Positive Developments in Oncology Treatments
Shilpa Medicare Limited has announced remarkable results from its Phase 3 clinical trial for OERIS™ (Ondansetron Extended-Release Injection), a groundbreaking solution designed to combat chemotherapy-induced nausea and vomiting (CINV). This innovative approach enhances patient experience by providing an effective antiemetic treatment.
Impressive Study Results
The Phase III trial achieved its primary and secondary objectives, showcasing significant advantages over traditional ondansetron injections. Conducted in India, the study involved 240 patients undergoing chemotherapy, focusing on the efficacy of OERIS™ in preventing nausea and vomiting.
The trial demonstrated a complete response of 89% in patients receiving OERIS™, compared to 82% for those on standard treatment. These findings signal a tremendous step forward for Shilpa Medicare, as they highlight the potential of OERIS™ to improve patient outcomes significantly.
Study Details
This multicenter, randomized, double-blind trial aimed at optimizing antiemetic therapy was crucial for patients experiencing moderately to highly emetogenic chemotherapy. It was designed to compare OERIS™ with conventional ondansetron injections.
Endpoints and Safety Profile
The primary endpoint confirmed that patients receiving OERIS™ reported no vomiting episodes within 120 hours post-chemotherapy. Furthermore, the trial monitored secondary outcomes, assessing safety, delayed-phase response, and patient tolerability, which aligned with high standards, showing no severe adverse events.
Transformative Impact of OERIS™
This single-injection solution provides protection against CINV for up to five days. OERIS™ eases the burden on patients by reducing the need for multiple daily medications or follow-up consultations, contributing significantly to enhanced convenience and compliance within clinical practice.
Vishnukant Bhutada, Managing Director of Shilpa Medicare Limited, expressed pride in announcing these results, stating that OERIS™ embodies the company’s mission to combine cutting-edge scientific research with a deep commitment to patient-centered care.
Looking Ahead: Regulatory and Market Strategies
The company intends to seek regulatory approval from the DCGI while preparing for global registration and commercialization through the 505(b)(2) pathway, targeting key markets, including the US. This step will facilitate timely access to OERIS™, potentially transforming how CINV is managed worldwide.
Understanding CINV and Market Opportunities
Chemotherapy-induced nausea and vomiting affect a significant percentage of patients, ranging from 70% to 80%, impacting their treatment experience and overall quality of life. The market for effective CINV therapies is substantial, valued at approximately USD 375 million. OERIS™ aims to meet this crucial need by providing long-acting, convenient solutions for patients and clinicians alike.
About Shilpa Medicare Limited
Shilpa Medicare is recognized as a leading pharmaceutical company in India, committed to developing high-quality active pharmaceutical ingredients (APIs), formulations, and biologics across oncology and specialty areas. The company is dedicated to advancing healthcare innovation and improving patient outcomes through research and development.
Frequently Asked Questions
What is OERIS™?
OERIS™ is an Ondansetron Extended-Release Injection designed to manage chemotherapy-induced nausea and vomiting effectively.
What were the results of the Phase 3 trial?
The trial achieved an 89% complete response rate in the OERIS™ group, significantly higher than the 82% in the conventional ondansetron group.
How does OERIS™ compare to traditional treatments?
OERIS™ offers a single injection option that provides extended antiemetic coverage for up to five days, simplifying treatment regimens.
What are the next steps for Shilpa Medicare?
Shilpa aims to file for regulatory approval and pursue global registration for OERIS™ under the 505(b)(2) pathway.
How many patients participated in the study?
The study included 240 patients who were administered chemotherapy.
